AAAAAA

   
Results: 1-16 |
Results: 16
SUPERSATURATING INFUSIONAL HUMANIZED ANTI-CD33 MONOCLONAL-ANTIBODY HUM195 IN MYELOGENOUS LEUKEMIA
Authors: CARON PC DUMONT L SCHEINBERG DA
Citation: Pc. Caron et al., SUPERSATURATING INFUSIONAL HUMANIZED ANTI-CD33 MONOCLONAL-ANTIBODY HUM195 IN MYELOGENOUS LEUKEMIA, Clinical cancer research, 4(6), 1998, pp. 1421-1428
THE BIOLOGICAL THERAPY OF ACUTE AND CHRONIC LEUKEMIA
Authors: CARON PC SCHEINBERG DA
Citation: Pc. Caron et Da. Scheinberg, THE BIOLOGICAL THERAPY OF ACUTE AND CHRONIC LEUKEMIA, Cancer investigation, 15(4), 1997, pp. 342-352
THE MULTIDRUG-RESISTANCE PHENOTYPE CONFERS IMMUNOLOGICAL RESISTANCE
Authors: WEISBURG JH CURCIO M CARON PC RAGHU G MECHETNER EB ROEPE PD SCHEINBERG DA
Citation: Jh. Weisburg et al., THE MULTIDRUG-RESISTANCE PHENOTYPE CONFERS IMMUNOLOGICAL RESISTANCE, The Journal of experimental medicine, 183(6), 1996, pp. 2699-2704
HIGH-DOSE INFUSIONAL HUMANIZED ANTI-CD33 M195 - PROSPECTS FOR TREATING MINIMAL DISEASE IN MYELOID-LEUKEMIA
Authors: CARON PC JURCIC JG DUMONT L TYSON D SCHEINBERG DA
Citation: Pc. Caron et al., HIGH-DOSE INFUSIONAL HUMANIZED ANTI-CD33 M195 - PROSPECTS FOR TREATING MINIMAL DISEASE IN MYELOID-LEUKEMIA, Blood, 88(10), 1996, pp. 859-859
INTERLEUKIN-2 ENHANCEMENT OF CYTOTOXICITY BY HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) IN MYELOGENOUS LEUKEMIA
Authors: CARON PC LAI LT SCHEINBERG DA
Citation: Pc. Caron et al., INTERLEUKIN-2 ENHANCEMENT OF CYTOTOXICITY BY HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) IN MYELOGENOUS LEUKEMIA, Clinical cancer research, 1(1), 1995, pp. 63-70
SEQUENTIAL TARGETED THERAPY FOR RELAPSED ACUTE PROMYELOCYTIC LEUKEMIAWITH ALL-TRANS-RETINOIC ACID AND ANTI-CD33 MONOCLONAL-ANTIBODY M195
Authors: JURCIC JG CARON PC MILLER WH YAO TJ MASLAK P FINN RD LARSON SM WARREL RP SCHEINBERG DA
Citation: Jg. Jurcic et al., SEQUENTIAL TARGETED THERAPY FOR RELAPSED ACUTE PROMYELOCYTIC LEUKEMIAWITH ALL-TRANS-RETINOIC ACID AND ANTI-CD33 MONOCLONAL-ANTIBODY M195, Leukemia, 9(2), 1995, pp. 244-248
RADIOLABELED ANTI-CD33 MONOCLONAL-ANTIBODY M195 FOR MYELOID LEUKEMIAS
Authors: JURCIC JG CARON PC NIKULA TK PAPADOPOULOS EB FINN RD GANSOW OA MILLER WH GEERLINGS MW WARRELL RP LARSON SM SCHEINBERG DA
Citation: Jg. Jurcic et al., RADIOLABELED ANTI-CD33 MONOCLONAL-ANTIBODY M195 FOR MYELOID LEUKEMIAS, Cancer research, 55(23), 1995, pp. 5908-5910
TARGETED THERAPY WITH HUMANIZED ANTI-CD33 MONOCLONAL-ANTIBODY (HUM195) REDUCES RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA
Authors: JURCIC JG CARON PC DEBLASIO A DUMONT L WARRELL RP SCHEINBERG DA
Citation: Jg. Jurcic et al., TARGETED THERAPY WITH HUMANIZED ANTI-CD33 MONOCLONAL-ANTIBODY (HUM195) REDUCES RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA, Blood, 86(10), 1995, pp. 2057-2057
INDUCTION OF APOPTOSIS OF HL-60 CELLS USING THE SHORT-RANGED ALPHA-PARTICLE EMITTING 213-BISMUTH CONJUGATED TO HUMANIZED ANTI-CD33 M195 - PROSPECTS FOR SELECTIVE SINGLE-CELL KILLING IN MYELOID-LEUKEMIA
Authors: CARON PC LAI LT MASLAK P NIKULA T JURCIC J SCHEINBERG DA
Citation: Pc. Caron et al., INDUCTION OF APOPTOSIS OF HL-60 CELLS USING THE SHORT-RANGED ALPHA-PARTICLE EMITTING 213-BISMUTH CONJUGATED TO HUMANIZED ANTI-CD33 M195 - PROSPECTS FOR SELECTIVE SINGLE-CELL KILLING IN MYELOID-LEUKEMIA, Blood, 86(10), 1995, pp. 2998-2998
MURINE AND HUMANIZED CONSTRUCTS OF MONOCLONAL-ANTIBODY M195 (ANTI-CD33) FOR THE THERAPY OF ACUTE MYELOGENOUS LEUKEMIA
Authors: CARON PC SCHWARTZ MA CO MS QUEEN C FINN RD GRAHAM MC DIVGI CR LARSON SM SCHEINBERG DA
Citation: Pc. Caron et al., MURINE AND HUMANIZED CONSTRUCTS OF MONOCLONAL-ANTIBODY M195 (ANTI-CD33) FOR THE THERAPY OF ACUTE MYELOGENOUS LEUKEMIA, Cancer, 73(3), 1994, pp. 1049-1056
A PHASE-1B TRIAL OF HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) INMYELOID-LEUKEMIA - SPECIFIC TARGETING WITHOUT IMMUNOGENICITY
Authors: CARON PC JURCIC JG SCOTT AM FINN RD DIVGI CR GRAHAM MC JUREIDINI IM SGOUROS G TYSON D OLD LJ LARSON SM SCHEINBERG DA
Citation: Pc. Caron et al., A PHASE-1B TRIAL OF HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) INMYELOID-LEUKEMIA - SPECIFIC TARGETING WITHOUT IMMUNOGENICITY, Blood, 83(7), 1994, pp. 1760-1768
ANTI-CD33 MONOCLONAL-ANTIBODY M195 FOR THE THERAPY OF MYELOID-LEUKEMIA
Authors: CARON PC SCHEINBERG DA
Citation: Pc. Caron et Da. Scheinberg, ANTI-CD33 MONOCLONAL-ANTIBODY M195 FOR THE THERAPY OF MYELOID-LEUKEMIA, Leukemia & lymphoma, 11, 1993, pp. 1-6
GENETICALLY-ENGINEERED DEGLYCOSYLATION OF THE VARIABLE DOMAIN INCREASES THE AFFINITY OF AN ANTI-CD33 MONOCLONAL-ANTIBODY
Authors: CO MS SCHEINBERG DA AVDALOVIC NM MCGRAW K VASQUEZ M CARON PC QUEEN C
Citation: Ms. Co et al., GENETICALLY-ENGINEERED DEGLYCOSYLATION OF THE VARIABLE DOMAIN INCREASES THE AFFINITY OF AN ANTI-CD33 MONOCLONAL-ANTIBODY, Molecular immunology, 30(15), 1993, pp. 1361
CLINICAL IMPLEMENTATION OF MODELING-BASED RADIOIMMUNOTHERAPY TREATMENT PLANNING - I-131 M195 ANTIBODY AGAINST CHRONIC MYELOGENOUS LEUKEMIA
Authors: SGOUROS G GRAHAM MC SCOTT A CARON PC DIVGI CR FINN R CARABASI M LARSON SM SCHEINBERG DA
Citation: G. Sgouros et al., CLINICAL IMPLEMENTATION OF MODELING-BASED RADIOIMMUNOTHERAPY TREATMENT PLANNING - I-131 M195 ANTIBODY AGAINST CHRONIC MYELOGENOUS LEUKEMIA, The Journal of nuclear medicine, 34(5), 1993, pp. 105-105
I-131-LABELED ANTI-CD33 (I-131-M195) MAY PROLONG DISEASE-FREE SURVIVAL (DFS) IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA (APL) AFTER REMISSIONINDUCTION WITH ALL-TRANS-RETINOIC ACID (RA)
Authors: JURCIC JG CARON PC MILLER WH YAO TJ MASLAK P FINN R LARSON SM WARRELL RP SCHEINBERG DA
Citation: Jg. Jurcic et al., I-131-LABELED ANTI-CD33 (I-131-M195) MAY PROLONG DISEASE-FREE SURVIVAL (DFS) IN RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA (APL) AFTER REMISSIONINDUCTION WITH ALL-TRANS-RETINOIC ACID (RA), Blood, 82(10), 1993, pp. 10000193-10000193
A PHASE-1B TRIAL OF HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) INMYELOID-LEUKEMIA - SPECIFIC TARGETING WITHOUT IMMUNOGENICITY
Authors: CARON PC JURCIC JG SCOTT AM FINN RD DIVGI CR GRAHAM MC JUREIDINI IM SGOUROS G TYSON D OLD LJ LARSON SM SCHEINBERG DA
Citation: Pc. Caron et al., A PHASE-1B TRIAL OF HUMANIZED MONOCLONAL-ANTIBODY M195 (ANTI-CD33) INMYELOID-LEUKEMIA - SPECIFIC TARGETING WITHOUT IMMUNOGENICITY, Blood, 82(10), 1993, pp. 10000329-10000329
Risultati: 1-16 |